Polarityte Inc (NASDAQ:PTE) COO Richard Hague Sells 3,885 Shares

Polarityte Inc (NASDAQ:PTE) COO Richard Hague sold 3,885 shares of the business’s stock in a transaction on Friday, October 11th. The shares were sold at an average price of $3.07, for a total transaction of $11,926.95.

Richard Hague also recently made the following trade(s):

  • On Friday, September 27th, Richard Hague sold 2,402 shares of Polarityte stock. The shares were sold at an average price of $3.56, for a total transaction of $8,551.12.

PTE opened at $2.82 on Friday. The firm’s 50-day simple moving average is $3.64 and its 200-day simple moving average is $5.81. The company has a debt-to-equity ratio of 0.06, a quick ratio of 6.68 and a current ratio of 6.72. Polarityte Inc has a twelve month low of $2.71 and a twelve month high of $18.17. The firm has a market cap of $72.83 million, a price-to-earnings ratio of -0.58 and a beta of 1.45.

Polarityte (NASDAQ:PTE) last posted its earnings results on Thursday, August 8th. The company reported ($0.92) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.05) by $0.13. The firm had revenue of $1.32 million during the quarter, compared to the consensus estimate of $1.57 million. During the same period in the previous year, the company posted ($0.74) EPS. The firm’s revenue for the quarter was up 312.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Polarityte Inc will post -4.14 EPS for the current fiscal year.

Several equities research analysts have issued reports on the stock. Oppenheimer set a $14.00 price target on shares of Polarityte and gave the company a “buy” rating in a report on Wednesday, August 21st. Zacks Investment Research lowered shares of Polarityte from a “buy” rating to a “hold” rating in a report on Friday. HC Wainwright initiated coverage on shares of Polarityte in a report on Monday, July 8th. They issued a “buy” rating and a $8.00 target price on the stock. ValuEngine raised shares of Polarityte from a “hold” rating to a “buy” rating in a report on Tuesday, July 2nd. Finally, Cantor Fitzgerald set a $50.00 target price on shares of Polarityte and gave the stock a “buy” rating in a report on Monday, September 23rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $19.38.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Comprehensive Portfolio Management LLC lifted its position in Polarityte by 19.5% during the 3rd quarter. Comprehensive Portfolio Management LLC now owns 33,700 shares of the company’s stock worth $109,000 after buying an additional 5,500 shares in the last quarter. Marshall Wace LLP lifted its position in Polarityte by 50.9% during the 2nd quarter. Marshall Wace LLP now owns 17,881 shares of the company’s stock worth $102,000 after buying an additional 6,031 shares in the last quarter. Marshall Wace North America L.P. acquired a new position in Polarityte during the 1st quarter worth about $73,000. Charles Schwab Investment Management Inc. lifted its position in Polarityte by 29.6% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 33,959 shares of the company’s stock worth $194,000 after buying an additional 7,755 shares in the last quarter. Finally, Northern Trust Corp lifted its position in Polarityte by 6.5% during the 2nd quarter. Northern Trust Corp now owns 149,783 shares of the company’s stock worth $853,000 after buying an additional 9,200 shares in the last quarter. Institutional investors and hedge funds own 41.51% of the company’s stock.

About Polarityte

PolarityTE, Inc, a biotechnology and regenerative biomaterials company, focuses on discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine and Contract Services.

Read More: Initial Coin Offering (ICO)

Insider Buying and Selling by Quarter for Polarityte (NASDAQ:PTE)

Receive News & Ratings for Polarityte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Polarityte and related companies with MarketBeat.com's FREE daily email newsletter.